J&J ATMI 2022
As part of the Johnson & Johnson Family of Companies, we’re proud to be recognised by the 2022 Access to Medicine Index (ATMI) as one of the top 2 companies working relentlessly to expand global equitable access to medicines and technologies in low and middle-income countries.
Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time Johnson & Johnson features as a top three performer by the Index. Our high rank is an important validation of our decades-long, deliberate, and focused strategy and a testament to our colleagues and partners around the world who work every day to enable access to our medicines and technologies in almost 100 lower- and middle-income countries.
Recognising much more needs to be done, we will continue to build on our approach to meet the needs of people today and the challenges the world faces tomorrow.